中国真实世界中使用存达®(盐酸苯达莫司汀)治疗惰性非霍奇金淋巴瘤的有效性和安全性研究
[Translation] A real-world study of the efficacy and safety of Cundam® (bendamustine hydrochloride) in the treatment of indolent non-Hodgkin's lymphoma in China
中国真实世界中使用存达®(盐酸苯达莫司汀)治疗惰性非霍奇金淋巴瘤的有效性和安全性研究
[Translation] A real-world study of the efficacy and safety of Cundam® (bendamustine hydrochloride) in the treatment of indolent non-Hodgkin's lymphoma in China
一项评估盐酸苯达莫司汀用于对利妥昔单抗治疗耐药的惰性非霍奇金淋巴瘤(NHL)中国患者的开放研究
[Translation] An open-label study evaluating bendamustine hydrochloride in Chinese patients with indolent non-Hodgkin lymphoma (NHL) resistant to rituximab
本研究的主要目的是确定使用利妥昔单抗或含利妥昔单抗的治疗后疾病出现进展的惰性非霍奇金淋巴瘤(NHL)患者对苯达莫司汀治疗的整体缓解率(ORR),包括完全缓解(CR)、部分缓解(PR)。
[Translation] The primary objective of this study was to determine the overall response rate (ORR), including complete response (CR) and partial response (PR), to bendamustine in patients with indolent non-Hodgkin lymphoma (NHL) who had disease progression after rituximab or rituximab-containing therapy.
/ Not yet recruitingPhase 2 Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways disease.
100 Clinical Results associated with Pharmachemie BV
0 Patents (Medical) associated with Pharmachemie BV
100 Deals associated with Pharmachemie BV
100 Translational Medicine associated with Pharmachemie BV